<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Zentiva, a leading European manufacturer of high–quality and affordable medicines, responds to the decision of the General Court of the European Union concerning the Urban Waste Water Treatment Directive (UWWTD) reiterating that the UWWTD, in its current form, poses a significant risk to the secure supply of essential medicines in Europe. Following the adoption of the Directive, despite major concerns raised by 16 EU Member States, in 2025 Zentiva filed a legal action to request annulment of the Directive to safeguard the secure supply of essential medicines for the patients who depend on them every day. The recent decision clarifies how the Court interprets legal standing under EU law. It concludes that Zentiva and other generic and off–patent medicine manufacturers are not considered individually affected, and therefore do not have a direct judicial route to challenge the Directive - even though its impact on the sector and on the medicines we supply across Europe is real and substantial. Importantly, the Court did not assess the substance of the case - including whether the Extended Producer Responsibility (EPR) scheme under the UWWTD is compatible with EU law or whether the cost model is workable, proportionate, or safe for securing the continuity of medicine supply. Zentiva CEO, Steffen Saltofte, who is also President of Medicines for Europe, stated: &#34;The UWWTD Directive has been approved and is already in the implementation phase. Its foundation is an assessment that has been scientifically disproven multiple times, yet it obliges the pharmaceutical and cosmetics industries to cover at least 80% of the costs for wastewater treatment in the fourth treatment stage. From the very beginning, we knew this was not feasible for the off–patent medicine industry. Our prices are mostly regulated, and the price for a daily dosage of an off–patent medicine is in the cent range. We simply cannot absorb these costs.&#34; If implemented without correction, the Directive may render many essential medicines economically unsustainable to produce. The result would directly affect patients across all EU Member States, reducing access to affordable treatments and increasing the risk of medicine shortages. Ultimately, patients would pay the price. The Court outcome does not resolve these long–standing issues - it leaves the substance of the Directive and its practical impact unaddressed, reinforcing the need for a political and policy–level correction before full implementation causes harm. The generics industry counts for 70% of all dispensed medicines, and 9 out of 10 critical medicines. If no further measures are taken and the Directive in its current form is transposed into national legislation across 27 countries, it is highly likely to lead to massive shortages. Saltofte further commented: &#34;As the CEO of a European-based company and President of Medicines for Europe, the representation of the off-patent medicine industry, I will not sit back and watch this happen. We will continue to insist on a solution that we must develop together - not in silos, and not without industry. This issue requires all stakeholders at one table to pause the implementation, repair it at EU level, and relaunch it in a workable way across Europe - ensuring clean water without jeopardizing the availability, accessibility, and affordability of healthcare for the people in Europe who depend on these medicines every day.&#34; What needs to happen next The Directive has been adopted and is entering national implementation, making political leadership and dialogue more urgent than ever. Zentiva calls for: <ul type="disc"> <li>A pause in the current implementation of the UWWTD at EU level, allowing an inclusive dialogue of EU institutions, Member States, water operators, patients, healthcare systems and industry,</li> <li>Conduct new independent studies, as part of a necessary repair of the Directive, based on sound science, proportionality and real world healthcare economics, to assess the impact on the availability, accessibility and affordability of medicines,</li> <li>A relaunch of the Directive in a workable form that delivers clean water without jeopardising the availability, accessibility and affordability of medicines for patients across Europe.</li> </ul> About Zentiva Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded together by a commitment to the people who depend on our medicines every day. Visit us at www.zentiva.com Logo - https://mma.prnewswire.com/media/2660891/5369762/Zentiva_Logo.jpg SOURCE Zentiva <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjIzJk5ld3NJdGVtSWQ9TE45MzEzNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjMwNjA0UFJfTkVXU19VU1BSX19fX19MTjkzMTM0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjIzJk5ld3NJdGVtSWQ9TE45MzEzNCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjMwNjA0UFJfTkVXU19VU1BSX19fX19MTjkzMTM0"/></div> </div></div>

513120

159859

Zentiva, a European medicine manufacturer, is calling for a halt to the implementation of the Urban Waste Water Treatment Directive (UWWTD) due to concerns it poses a risk to the supply of essential medicines. The General Court of the EU ruled that Zentiva lacks legal standing to challenge the Directive, which could lead to increased costs for off-patent medicines. Zentiva's CEO emphasizes the need for a collaborative solution to ensure the availability and affordability of healthcare while maintaining clean water standards. The company urges for new studies and a relaunch of the Directive to address these issues.

prnewswire

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

VG Health

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Direxion S&P Biotech Bull 3X

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

iShares Global Healthcare

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares US Pharma

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Health Care Select Sector SPDR

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ark Genomic Revolution ETF

06:04 ETZentiva Demands EU-Level Stop-the-Clock on the UWWTD to Protect Medicine Availability